Given investment horizon of 30 days, Nektar Therapeutics is expected to under-perform the Alkermes. In addition to that, Nektar is 1.12 times more volatile than Alkermes Inc.. It trades about -0.17 of its total potential returns per unit of risk. Alkermes Inc. is currently generating about -0.15 per unit of volatility. If you would invest 1,788 in Alkermes Inc. on April 26, 2012 and sell it today you would lose (174.00) from holding Alkermes Inc. or give up 9.73% of portfolio value over 30 days.
Diversification
Weak diversification
Overlapping area represents amount of risk that can be diversified away by holding Nektar Therapeutics and Alkermes Inc. in the same portfolio (assuming nothing else is changed)
USA 
Select Assests
Optimize Portfolio
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatilities
Import Equities
Search Equities
